These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15102870)

  • 1. Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75.
    Wong SL; Lau DT; Baughman SA; Fotheringham N; Menchaca D; Garnick MB
    J Clin Pharmacol; 2004 May; 44(5):495-502. PubMed ID: 15102870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group.
    Garnick MB; Campion M
    Mol Urol; 2000; 4(3):275-7. PubMed ID: 11062384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study.
    Erb K; Pechstein B; Schueler A; Engel J; Hermann R
    Clin Pharmacol Ther; 2000 Jun; 67(6):660-9. PubMed ID: 10872648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer.
    Wong SL; Lau DT; Baughman SA; Menchaca D; Garnick MB
    Clin Pharmacol Ther; 2003 Apr; 73(4):304-11. PubMed ID: 12709720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study.
    Beer TM; Ryan C; Bhat G; Garnick M;
    Anticancer Drugs; 2006 Oct; 17(9):1075-9. PubMed ID: 17001181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of two different delivery systems on gonadotropin-releasing hormone (GnRH) antagonist-induced suppression of gonadotropins and testosterone in man.
    Salameh W; Bhasin S; Steiner BS; McAdams LA; Peterson M; Rivier JE; Vale WW; Swerdloff RS
    J Androl; 1994; 15(1):22-8. PubMed ID: 8188535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
    Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy.
    Beer TM; Garzotto M; Eilers KM; Lemmon D
    J Urol; 2003 May; 169(5):1738-41. PubMed ID: 12686821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The direct pituitary effect of testosterone to inhibit gonadotropin secretion in men is partially mediated by aromatization to estradiol.
    Bagatell CJ; Dahl KD; Bremner WJ
    J Androl; 1994; 15(1):15-21. PubMed ID: 8188534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of new testosterone transdermal therapeutic systems in gonadotropin-releasing hormone antagonist-suppressed normal men.
    Rolf C; Gottschalk I; Behre HM; Rauch C; Thyroff U; Nieschlag E
    Exp Clin Endocrinol Diabetes; 1999; 107(1):63-9. PubMed ID: 10077358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel formulations of cetrorelix acetate in healthy men: pharmacodynamic effects and noncompartmental pharmacokinetics.
    Erb K; Junge K; Pechstein B; Schneider E; Derendorf H; Hermann R
    J Clin Pharmacol; 2002 Sep; 42(9):995-1001. PubMed ID: 12211225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follicle-stimulating hormone (FSH) escape during chronic gonadotropin-releasing hormone (GnRH) agonist and testosterone treatment.
    Bhasin S; Berman N; Swerdloff RS
    J Androl; 1994; 15(5):386-91. PubMed ID: 7860418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.
    Beer TM; Garzotto M; Eilers KM; Lemmon D; Wersinger EM
    Urology; 2004 Feb; 63(2):342-7. PubMed ID: 14972486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men.
    Bagatell CJ; Conn PM; Bremner WJ
    Fertil Steril; 1993 Oct; 60(4):680-5. PubMed ID: 8405525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age-related decrease in hypothalamic gonadotropin-releasing hormone (GnRH) gene expression, but not pituitary responsiveness to GnRH, in the male Brown Norway rat.
    Gruenewald DA; Naai MA; Marck BT; Matsumoto AM
    J Androl; 2000; 21(1):72-84. PubMed ID: 10670522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.
    Debruyne F; Bhat G; Garnick MB
    Future Oncol; 2006 Dec; 2(6):677-96. PubMed ID: 17155895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer.
    McLeod D; Zinner N; Tomera K; Gleason D; Fotheringham N; Campion M; Garnick MB;
    Urology; 2001 Nov; 58(5):756-61. PubMed ID: 11711355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative response of rams and bulls to long-term treatment with gonadotropin-releasing hormone analogs.
    Jiménez-Severiano H; D'Occhio MJ; Lunstra DD; Mussard ML; Davis TL; Enright WJ; Kinder JE
    Anim Reprod Sci; 2007 Apr; 98(3-4):204-24. PubMed ID: 16616998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.